Cancer Genetics Inc (CGIX) 10.15 $CGIX
Coping with Cancer Effectively Using Enhanced Diagnosis and Treatment
GlobeNewswire - Wed Jul 30, 2:45AM CDT
via PRWEB - Cancer Therapy-2014 will be an unique platform, which will bring together the renowned oncologists, scientists and scholars in pursuit of unraveling the mysteries of cancer under one roof. In the Keynote forum of Cancer Therapy-2014 many eminent experts in the field like Prof. Rudolf Wank, Immunotherapy Research Center, Germany; Sudhakar Yakkanti, SRI International, USA will mark their presence. A special session on "Bioactive Natural Products for Cancer Prevention and Therapy" will be chaired by Dr. Anupam Bishayee, Assistant Dean and Chair, American University of Health Sciences. This significant session will feature expertise presentations like "Genistein in prevention and treatment of cancer", "Effect of phytochemicals on breast cancer cells", "Control colorectal cancer" and "Effects of herbs on major cancers".
Cancer Genetics, Inc. to Present at the Canaccord Genuity 34th Annual Growth Conference
GlobeNewswire - Tue Jul 22, 7:00AM CDT
Cancer Genetics, Inc. (Nasdaq:CGIX) ("CGI" or the "Company"
, an emerging leader in DNA-based diagnostics, today announced that an overview of the Company's business and commercial strategy will be given by CGI's Chief Executive Officer, Panna Sharma, at the Canaccord Genuity 34 Annual Growth Conference, being held in Boston August 13-14, 2014.
Cancer Genetics Announces Acquisition of Gentris Corporation, a Leading Global Pharmacogenomics Company, and Increases Contract Backlog to Over $18 Million
GlobeNewswire - Mon Jul 21, 6:45AM CDT
-- Acquisition Adds Contracts With Five of the Top Biopharma Companies Globally
Research and Markets: Global Genetic Testing Market - Industry Analysis And Market Forecast 2014-2020
Business Wire - Fri Jun 27, 1:37PM CDT
Research and Markets (http://www.researchandmarkets.com/research/gtxthx/global_genetic) has announced the addition of the "Global Genetic Testing Market - Industry Analysis And Market Forecast 2014-2020" report to their offering.
Global Genetic Testing Market - Industry Analysis And Market Forecast 2014-2020
M2 - Fri Jun 27, 5:41AM CDT
Research and Markets (http://www.researchandmarkets.com/research/77v9bc/global_genetic) has announced the addition of the "Global Genetic Testing Market - Industry Analysis And Market Forecast 2014-2020" report to their offering. Genetic testing is the analysis of genes, chromosomes, or proteins to help predict the risk of disease, identify carriers (individuals who do not have the disease but have a copy of the disease gene) of disease, diagnose disease, or determine the likely course of a disease. Cytogenetics, Molecular Genetics, Cancer Genetics, Prenatal Screening and Prenatal diagnosis are type of genetic tests that involves examining a person's genetic material taken from cells in a sample of blood or, occasionally, from other body fluids or tissues. Genetic Testing market growth is driven by increasing adoption of oncology applications, growing public awareness and demand for personalized medicine. It advances with aging population and a subsequent rise in the number of chronic diseases, and increasing incidence of cancer cases are the other factors propelling growth in the genetic testing market. Genetic testing represents the most rapidly expanding segment of the molecular diagnostics market worldwide. Growing incidence of genetic diseases unravels new opportunities for genetic testing. Key Topics Covered: 1 INTRODUCTION 2 GENETIC TESTING MARKET OVERVIEW 3 GLOBAL GENETIC TESTING - MARKET FORCES 4 GLOBAL GENETIC TESTING MARKET, BY TYPES 5 GENETIC TESTING MARKET, BY GEOGRAPHY 6 COMPETITIVE LANDSCAPE 7 COMPANY PROFILES 8 DISCLAIMER Companies Mentioned: - Andme, Inc. - Abbott Molecular - Ariosa Diagnostics, Inc - Biocartis Sa - Biohelix Corporation (Wholly Owned Subsidiary Of Quidel) - Biomerieux S.A. - Celera Corporation - Cepheid - Daan Diagnostics Ltd. - Ekf Diagnostics Holdings Plc - Genentech, Inc. - Genomictree, Inc. - Htg Molecular Diagnostics, Inc. - Illumina, Inc - Integragen S.A - Laboratory Corporation Of America Holdings - Luminex Corporation - Molecularmd, Corp. - Myriad Genetics, Inc. - Natera, Inc. - Oxford Biodynamics Limited - Pacific Biosciences Of California, Inc. - Perkinelmer, Inc. - Qiagen N.V. - Roche Diagnostics Limited - Seegene, Inc. - Sequenom, Inc. - Siemens Healthcare - Transgenomic, Inc. For more information visit http://www.researchandmarkets.com/research/77...al_genetic
BTV Reports on Roche, Sorrento Therapeutics Takes on a Goliath, Plus Biotech Up-and-Comers
Marketwire - Thu Jun 26, 5:01AM CDT
BTV-Business Television goes on location to bring investors expert analyst commentary and stories on emerging companies for their portfolio.
Cancer Genetics to Acquire Gentris Corporation, a Global Leader in Pharmacogenomic Profiling for Therapeutic Development, Companion Diagnostics & Clinical Trials
GlobeNewswire - Mon Jun 23, 7:37AM CDT
Cancer Genetics, Inc. (Nasdaq:CGIX), a DNA-based diagnostics company focused on developing genomic-based oncology tests and services, today announced the signing of a non-binding Letter of Intent (LOI) to acquire privately held Gentris Corporation, a leader in pharmacogenomics solutions, biomarker testing and biorepository services for approximately $4.75 million, comprised of $3.25 million in cash, $1.5 million in CGI stock as well as additional performance-based earnouts of up to $1.5 million.
Cancer Genetics, Inc. Announces Partnership With AstraZeneca to Provide Biomarker & Molecular Based Testing
GlobeNewswire - Mon Jun 09, 7:09AM CDT
-- Agreement Expands Reach of Cancer Genetics' Molecular Diagnostic & Biomarker Services
RedChip Issues Research Update on Cancer Genetics
GlobeNewswire - Thu Jun 05, 9:39AM CDT
RedChip Companies, Inc., today announced it has issued a research profile on Cancer Genetics, Inc. (Nasdaq:CGIX), an emerging leader in DNA-based cancer diagnostics that personalizes the clinical management of difficult-to-diagnose cancers.
Cancer Genetics, Inc. Partners With Leading Southwest Gynecological Pathology Lab to Provide Great Availability of FHACT(R), a Non-Invasive, Genomic Test to Guide the Detection and Management of Cervical Cancer
GlobeNewswire - Tue Jun 03, 9:25AM CDT
-- Collaboration With PathAdvantage Introduces Precision Testing for Cervical Cancer Into The Rapidly Growing Metro Dallas and North Texas Market
LifeSci Advisors Initiates Coverage of Cancer Genetics, Inc.
Marketwire - Tue Apr 01, 8:03AM CDT
LifeSci Advisors, LLC, a leading provider of investment research and investor relations services in the life sciences sector, today announced that it has initiated coverage of Cancer Genetics, Inc. (NASDAQ: CGIX), a diagnostics company developing genomic-based oncology tests and services to enhance disease management and patient outcomes. The Company offers a wide-range of proprietary and non-proprietary tests to support patients during all aspects of their care, from initial diagnosis to prognosis, and determination of optimal treatment options. Oncology is moving towards categorizing cancers by their molecular signature rather than the location in the body, and there is a continuing need for wider access to diagnostic toolkits. Cancer Genetics collaborates with leading research institutions for biomarker development, with community hospitals to improve patient care, and with biotechnology and pharmaceutical companies to provide clinical trial services.
Five Star Quality Care (FVE) in Focus: Stock Tumbles 9.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 28, 8:40AM CDT
Five Star Quality Care saw a big move last session, as the company’s shares fell nearly 10% on the day
RedChip TV Announces Lineup for This Week's Show on Fox Business and Bloomberg
GlobeNewswire - Thu Mar 27, 9:56AM CDT
RedChip Companies, Inc. ("RedChip" , an international small-cap research, investor relations, and media company, today announced that "The RedChip Money Report: Small Stocks Big Money" television program will feature emerging growth companies on Fox Business nationwide on Thursday, March 27, 2014 at 10:00 p.m. Pacific (1 a.m. EDT). The show will also air on Bloomberg U.K. Saturday, March 29, 2014 at 12:30 a.m. GMT; on Bloomberg Europe on Sunday, March 30, 2014 at 8:30 a.m. and 3:30 p.m. GMT; and on Bloomberg Asia on Sunday March 30, 2014 at 3:30 p.m. HKT.
Cancer Genetics, Inc. Announces Fourth Quarter and Year-End 2013 Results, Provides Corporate Update
GlobeNewswire - Wed Mar 26, 3:01PM CDT
-- 72% Year-Over-Year Revenue Growth During Fourth Quarter 2013
Cancer Genetics to Report Fourth Quarter and Year-End 2013 Results on Wednesday, March 26, 2014
GlobeNewswire - Fri Mar 21, 7:00AM CDT
Cancer Genetics, Inc. (Nasdaq:CGIX) ("CGI" or the "Company" , an emerging leader in DNA-based diagnostics, announced today that it will report its results for the fourth quarter and year-end 2013 after the market close on Wednesday, March 26, 2014. The company will also hold a live investor conference call and webcast at 4:30pm Eastern/1:30pm Pacific.
Cancer Genetics Appoints Edward J. Sitar as Chief Financial Officer
GlobeNewswire - Mon Mar 17, 7:08AM CDT
Cancer Genetics (Nasdaq:CGIX), an emerging leader in DNA-based diagnostics, announced today that effective April 1, 2014, it has appointed Edward J. Sitar, CPA as Chief Financial Officer. Mr. Sitar will be responsible for all Corporate Finance and Accounting activities for Cancer Genetics.
Cancer Genetics Announces Compelling Diagnostic Sensitivity (99%) and Accuracy (93%) for Its Patent-Protected Genomic Kidney Cancer Test
GlobeNewswire - Wed Mar 05, 7:01AM CST
Cancer Genetics, Inc. (Nasdaq:CGIX) ("CGI" announced today the results of a collaborative study conducted with The Cleveland Clinic to validate CGI's kidney cancer microarray test. The CGI kidney cancer microarray facilitates the diagnosis, sub-typing, and outcome prediction of kidney cancer patients. This study demonstrated that the diagnostic sensitivity of the test is 93%, with 99% specificity. The clinical validation study was performed using samples from 188 kidney cancer patients treated at the Cleveland Clinic. Accurately diagnosing kidney cancer using pathology alone is challenging, and can delay time to first treatment if surgical resections are required.
BioTelemetry, Inc. (BEAT) Surges: Stock Moves 13.6% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Feb 28, 8:21AM CST
BioTelemetry, Inc. (BEAT) was a big mover last session, as the company saw its shares rise by roughly 14% on the day.
Coping with Cancer Effectively Using Enhanced Diagnosis and Treatment
GlobeNewswire - Wed Jul 30, 2:45AM CDT
via PRWEB - Cancer Therapy-2014 will be an unique platform, which will bring together the renowned oncologists, scientists and scholars in pursuit of unraveling the mysteries of cancer under one roof. In the Keynote forum of Cancer Therapy-2014 many eminent experts in the field like Prof. Rudolf Wank, Immunotherapy Research Center, Germany; Sudhakar Yakkanti, SRI International, USA will mark their presence. A special session on "Bioactive Natural Products for Cancer Prevention and Therapy" will be chaired by Dr. Anupam Bishayee, Assistant Dean and Chair, American University of Health Sciences. This significant session will feature expertise presentations like "Genistein in prevention and treatment of cancer", "Effect of phytochemicals on breast cancer cells", "Control colorectal cancer" and "Effects of herbs on major cancers".
Cancer Genetics, Inc. to Present at the Canaccord Genuity 34th Annual Growth Conference
GlobeNewswire - Tue Jul 22, 7:00AM CDT
Cancer Genetics, Inc. (Nasdaq:CGIX) ("CGI" or the "Company"
, an emerging leader in DNA-based diagnostics, today announced that an overview of the Company's business and commercial strategy will be given by CGI's Chief Executive Officer, Panna Sharma, at the Canaccord Genuity 34 Annual Growth Conference, being held in Boston August 13-14, 2014. Cancer Genetics Announces Acquisition of Gentris Corporation, a Leading Global Pharmacogenomics Company, and Increases Contract Backlog to Over $18 Million
GlobeNewswire - Mon Jul 21, 6:45AM CDT
-- Acquisition Adds Contracts With Five of the Top Biopharma Companies Globally
Research and Markets: Global Genetic Testing Market - Industry Analysis And Market Forecast 2014-2020
Business Wire - Fri Jun 27, 1:37PM CDT
Research and Markets (http://www.researchandmarkets.com/research/gtxthx/global_genetic) has announced the addition of the "Global Genetic Testing Market - Industry Analysis And Market Forecast 2014-2020" report to their offering.
Global Genetic Testing Market - Industry Analysis And Market Forecast 2014-2020
M2 - Fri Jun 27, 5:41AM CDT
Research and Markets (http://www.researchandmarkets.com/research/77v9bc/global_genetic) has announced the addition of the "Global Genetic Testing Market - Industry Analysis And Market Forecast 2014-2020" report to their offering. Genetic testing is the analysis of genes, chromosomes, or proteins to help predict the risk of disease, identify carriers (individuals who do not have the disease but have a copy of the disease gene) of disease, diagnose disease, or determine the likely course of a disease. Cytogenetics, Molecular Genetics, Cancer Genetics, Prenatal Screening and Prenatal diagnosis are type of genetic tests that involves examining a person's genetic material taken from cells in a sample of blood or, occasionally, from other body fluids or tissues. Genetic Testing market growth is driven by increasing adoption of oncology applications, growing public awareness and demand for personalized medicine. It advances with aging population and a subsequent rise in the number of chronic diseases, and increasing incidence of cancer cases are the other factors propelling growth in the genetic testing market. Genetic testing represents the most rapidly expanding segment of the molecular diagnostics market worldwide. Growing incidence of genetic diseases unravels new opportunities for genetic testing. Key Topics Covered: 1 INTRODUCTION 2 GENETIC TESTING MARKET OVERVIEW 3 GLOBAL GENETIC TESTING - MARKET FORCES 4 GLOBAL GENETIC TESTING MARKET, BY TYPES 5 GENETIC TESTING MARKET, BY GEOGRAPHY 6 COMPETITIVE LANDSCAPE 7 COMPANY PROFILES 8 DISCLAIMER Companies Mentioned: - Andme, Inc. - Abbott Molecular - Ariosa Diagnostics, Inc - Biocartis Sa - Biohelix Corporation (Wholly Owned Subsidiary Of Quidel) - Biomerieux S.A. - Celera Corporation - Cepheid - Daan Diagnostics Ltd. - Ekf Diagnostics Holdings Plc - Genentech, Inc. - Genomictree, Inc. - Htg Molecular Diagnostics, Inc. - Illumina, Inc - Integragen S.A - Laboratory Corporation Of America Holdings - Luminex Corporation - Molecularmd, Corp. - Myriad Genetics, Inc. - Natera, Inc. - Oxford Biodynamics Limited - Pacific Biosciences Of California, Inc. - Perkinelmer, Inc. - Qiagen N.V. - Roche Diagnostics Limited - Seegene, Inc. - Sequenom, Inc. - Siemens Healthcare - Transgenomic, Inc. For more information visit http://www.researchandmarkets.com/research/77...al_genetic
BTV Reports on Roche, Sorrento Therapeutics Takes on a Goliath, Plus Biotech Up-and-Comers
Marketwire - Thu Jun 26, 5:01AM CDT
BTV-Business Television goes on location to bring investors expert analyst commentary and stories on emerging companies for their portfolio.
Cancer Genetics to Acquire Gentris Corporation, a Global Leader in Pharmacogenomic Profiling for Therapeutic Development, Companion Diagnostics & Clinical Trials
GlobeNewswire - Mon Jun 23, 7:37AM CDT
Cancer Genetics, Inc. (Nasdaq:CGIX), a DNA-based diagnostics company focused on developing genomic-based oncology tests and services, today announced the signing of a non-binding Letter of Intent (LOI) to acquire privately held Gentris Corporation, a leader in pharmacogenomics solutions, biomarker testing and biorepository services for approximately $4.75 million, comprised of $3.25 million in cash, $1.5 million in CGI stock as well as additional performance-based earnouts of up to $1.5 million.
Cancer Genetics, Inc. Announces Partnership With AstraZeneca to Provide Biomarker & Molecular Based Testing
GlobeNewswire - Mon Jun 09, 7:09AM CDT
-- Agreement Expands Reach of Cancer Genetics' Molecular Diagnostic & Biomarker Services
RedChip Issues Research Update on Cancer Genetics
GlobeNewswire - Thu Jun 05, 9:39AM CDT
RedChip Companies, Inc., today announced it has issued a research profile on Cancer Genetics, Inc. (Nasdaq:CGIX), an emerging leader in DNA-based cancer diagnostics that personalizes the clinical management of difficult-to-diagnose cancers.
Cancer Genetics, Inc. Partners With Leading Southwest Gynecological Pathology Lab to Provide Great Availability of FHACT(R), a Non-Invasive, Genomic Test to Guide the Detection and Management of Cervical Cancer
GlobeNewswire - Tue Jun 03, 9:25AM CDT
-- Collaboration With PathAdvantage Introduces Precision Testing for Cervical Cancer Into The Rapidly Growing Metro Dallas and North Texas Market
LifeSci Advisors Initiates Coverage of Cancer Genetics, Inc.
Marketwire - Tue Apr 01, 8:03AM CDT
LifeSci Advisors, LLC, a leading provider of investment research and investor relations services in the life sciences sector, today announced that it has initiated coverage of Cancer Genetics, Inc. (NASDAQ: CGIX), a diagnostics company developing genomic-based oncology tests and services to enhance disease management and patient outcomes. The Company offers a wide-range of proprietary and non-proprietary tests to support patients during all aspects of their care, from initial diagnosis to prognosis, and determination of optimal treatment options. Oncology is moving towards categorizing cancers by their molecular signature rather than the location in the body, and there is a continuing need for wider access to diagnostic toolkits. Cancer Genetics collaborates with leading research institutions for biomarker development, with community hospitals to improve patient care, and with biotechnology and pharmaceutical companies to provide clinical trial services.
Five Star Quality Care (FVE) in Focus: Stock Tumbles 9.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 28, 8:40AM CDT
Five Star Quality Care saw a big move last session, as the company’s shares fell nearly 10% on the day
RedChip TV Announces Lineup for This Week's Show on Fox Business and Bloomberg
GlobeNewswire - Thu Mar 27, 9:56AM CDT
RedChip Companies, Inc. ("RedChip"
, an international small-cap research, investor relations, and media company, today announced that "The RedChip Money Report: Small Stocks Big Money" television program will feature emerging growth companies on Fox Business nationwide on Thursday, March 27, 2014 at 10:00 p.m. Pacific (1 a.m. EDT). The show will also air on Bloomberg U.K. Saturday, March 29, 2014 at 12:30 a.m. GMT; on Bloomberg Europe on Sunday, March 30, 2014 at 8:30 a.m. and 3:30 p.m. GMT; and on Bloomberg Asia on Sunday March 30, 2014 at 3:30 p.m. HKT. Cancer Genetics, Inc. Announces Fourth Quarter and Year-End 2013 Results, Provides Corporate Update
GlobeNewswire - Wed Mar 26, 3:01PM CDT
-- 72% Year-Over-Year Revenue Growth During Fourth Quarter 2013
Cancer Genetics to Report Fourth Quarter and Year-End 2013 Results on Wednesday, March 26, 2014
GlobeNewswire - Fri Mar 21, 7:00AM CDT
Cancer Genetics, Inc. (Nasdaq:CGIX) ("CGI" or the "Company"
, an emerging leader in DNA-based diagnostics, announced today that it will report its results for the fourth quarter and year-end 2013 after the market close on Wednesday, March 26, 2014. The company will also hold a live investor conference call and webcast at 4:30pm Eastern/1:30pm Pacific. Cancer Genetics Appoints Edward J. Sitar as Chief Financial Officer
GlobeNewswire - Mon Mar 17, 7:08AM CDT
Cancer Genetics (Nasdaq:CGIX), an emerging leader in DNA-based diagnostics, announced today that effective April 1, 2014, it has appointed Edward J. Sitar, CPA as Chief Financial Officer. Mr. Sitar will be responsible for all Corporate Finance and Accounting activities for Cancer Genetics.
Cancer Genetics Announces Compelling Diagnostic Sensitivity (99%) and Accuracy (93%) for Its Patent-Protected Genomic Kidney Cancer Test
GlobeNewswire - Wed Mar 05, 7:01AM CST
Cancer Genetics, Inc. (Nasdaq:CGIX) ("CGI"
announced today the results of a collaborative study conducted with The Cleveland Clinic to validate CGI's kidney cancer microarray test. The CGI kidney cancer microarray facilitates the diagnosis, sub-typing, and outcome prediction of kidney cancer patients. This study demonstrated that the diagnostic sensitivity of the test is 93%, with 99% specificity. The clinical validation study was performed using samples from 188 kidney cancer patients treated at the Cleveland Clinic. Accurately diagnosing kidney cancer using pathology alone is challenging, and can delay time to first treatment if surgical resections are required. BioTelemetry, Inc. (BEAT) Surges: Stock Moves 13.6% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Feb 28, 8:21AM CST
BioTelemetry, Inc. (BEAT) was a big mover last session, as the company saw its shares rise by roughly 14% on the day.
